Patient characteristics according to the stage at initial NLPHL diagnosis
| Stage at initial diagnosis . | Early, N = 61 . | Intermediate, N = 14 . | Advanced, N = 24 . | Total, N = 99 . |
|---|---|---|---|---|
| Sex | ||||
| Female | 13 (21) | 6 (43) | 5 (21) | 24 (24) |
| Male | 48 (79) | 8 (57) | 19 (79) | 75 (76) |
| Median age at initial diagnosis (range), y | 39 (16-67) | 38.5 (17-75) | 42.5 (22-56) | 40 (16-75) |
| First-line treatment | ||||
| RT alone | 20 (33) | 0 | 0 | 20 (20) |
| CT ± RT | 35 (57) | 14 (100) | 24 (100) | 73 (74) |
| Anti-CD20 Ab | 6 (10) | 0 | 0 | 6 (6) |
| Observation time | ||||
| Median (range), y | 10.2 (7.7-12.0) | 10.9 (7.5-14.1) | 12.5 (8.3-16.4) | 11.2 (8.9-12.0) |
| Time to progression/first relapse | ||||
| Median (range), y | 3.7 (0.2-18.4) | 4.5 (0.7-11.0) | 3.2 (0.4-19.4) | 3.7 (0.2-19.4) |
| Year of event, from baseline, n (%) | ||||
| 1 | 15 (25) | 2 (14) | 9 (38) | 26 (26) |
| 2-3 | 10 (16) | 1 (7) | 2 (8) | 13 (13) |
| 4-5 | 11 (18) | 5 (36) | 5 (21) | 21 (21) |
| 6-10 | 12 (20) | 4 (29) | 7 (29) | 23 (23) |
| >10 | 13 (21) | 2 (14 | 1 (4) | 16 (16) |
| Second-line treatment, n (%) | ||||
| Year of event, n (%) | ||||
| Single-agent anti-CD20 Ab or RT alone | 25 (41) | 4(29) | 8 (33) | 37(37) |
| 1 | 7 (28) | — | 2 (25) | 9 (24) |
| 2-3 | 4 (16) | — | 2 (25) | 6 (16) |
| 4-5 | 3 (12) | 2 (50) | 1 (13) | 6 (16) |
| 6-10 | 5 (20) | 1 (25) | 2 (25) | 9 (24) |
| >10 | 6 (24) | 1 (25) | 1 (13) | 8 (22) |
| CT ± anti-CD20 Ab ± RT | 21 (34) | 2 (14) | 4 (17) | 27 (27) |
| 1 | 4 (19) | — | 3 (75) | 7 (26) |
| 2-3 | 3 (14) | — | — | 3 (11) |
| 4-5 | 3 (14) | — | — | 3 (11) |
| 6-10 | 5 (24) | 1 (50) | 1 (25) | 7 (26) |
| >10 | 6 (29) | 1 (50) | — | 7 (26) |
| HDCT + ASCT | 13 (21) | 6 (43) | 12 (50) | 31 (31) |
| 1 | 3 (23) | 1 (17) | 4 (33) | 8 (26) |
| 2-3 | 3 (23) | 1 (17) | — | 4 (13) |
| 4-5 | 5 (39) | 2 (33) | 4 (33) | 11 (36) |
| 6-10 | 2 (15) | 2 (33 | 4 (33) | 8 (26) |
| No therapy | 2 (3) | 2 (14) | — | 4 (4) |
| 1 | 1 (5) | 1 (50) | 2 (50) | |
| 4-5 | — | 1 (50) | 1 (25) | |
| >10 | 1 (50) | — | 1 (25) |
| Stage at initial diagnosis . | Early, N = 61 . | Intermediate, N = 14 . | Advanced, N = 24 . | Total, N = 99 . |
|---|---|---|---|---|
| Sex | ||||
| Female | 13 (21) | 6 (43) | 5 (21) | 24 (24) |
| Male | 48 (79) | 8 (57) | 19 (79) | 75 (76) |
| Median age at initial diagnosis (range), y | 39 (16-67) | 38.5 (17-75) | 42.5 (22-56) | 40 (16-75) |
| First-line treatment | ||||
| RT alone | 20 (33) | 0 | 0 | 20 (20) |
| CT ± RT | 35 (57) | 14 (100) | 24 (100) | 73 (74) |
| Anti-CD20 Ab | 6 (10) | 0 | 0 | 6 (6) |
| Observation time | ||||
| Median (range), y | 10.2 (7.7-12.0) | 10.9 (7.5-14.1) | 12.5 (8.3-16.4) | 11.2 (8.9-12.0) |
| Time to progression/first relapse | ||||
| Median (range), y | 3.7 (0.2-18.4) | 4.5 (0.7-11.0) | 3.2 (0.4-19.4) | 3.7 (0.2-19.4) |
| Year of event, from baseline, n (%) | ||||
| 1 | 15 (25) | 2 (14) | 9 (38) | 26 (26) |
| 2-3 | 10 (16) | 1 (7) | 2 (8) | 13 (13) |
| 4-5 | 11 (18) | 5 (36) | 5 (21) | 21 (21) |
| 6-10 | 12 (20) | 4 (29) | 7 (29) | 23 (23) |
| >10 | 13 (21) | 2 (14 | 1 (4) | 16 (16) |
| Second-line treatment, n (%) | ||||
| Year of event, n (%) | ||||
| Single-agent anti-CD20 Ab or RT alone | 25 (41) | 4(29) | 8 (33) | 37(37) |
| 1 | 7 (28) | — | 2 (25) | 9 (24) |
| 2-3 | 4 (16) | — | 2 (25) | 6 (16) |
| 4-5 | 3 (12) | 2 (50) | 1 (13) | 6 (16) |
| 6-10 | 5 (20) | 1 (25) | 2 (25) | 9 (24) |
| >10 | 6 (24) | 1 (25) | 1 (13) | 8 (22) |
| CT ± anti-CD20 Ab ± RT | 21 (34) | 2 (14) | 4 (17) | 27 (27) |
| 1 | 4 (19) | — | 3 (75) | 7 (26) |
| 2-3 | 3 (14) | — | — | 3 (11) |
| 4-5 | 3 (14) | — | — | 3 (11) |
| 6-10 | 5 (24) | 1 (50) | 1 (25) | 7 (26) |
| >10 | 6 (29) | 1 (50) | — | 7 (26) |
| HDCT + ASCT | 13 (21) | 6 (43) | 12 (50) | 31 (31) |
| 1 | 3 (23) | 1 (17) | 4 (33) | 8 (26) |
| 2-3 | 3 (23) | 1 (17) | — | 4 (13) |
| 4-5 | 5 (39) | 2 (33) | 4 (33) | 11 (36) |
| 6-10 | 2 (15) | 2 (33 | 4 (33) | 8 (26) |
| No therapy | 2 (3) | 2 (14) | — | 4 (4) |
| 1 | 1 (5) | 1 (50) | 2 (50) | |
| 4-5 | — | 1 (50) | 1 (25) | |
| >10 | 1 (50) | — | 1 (25) |
Second-line chemotherapy protocols: doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP); dexamethasone, cytarabine, cisplatin (DHAP); bendamustine/gemcitabine/prednisone.
±RT, with or without consolidating radiotherapy; —, no patients meet the respective criteria.